Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Follicular Lymphoma Grade III (FL III°)

Janssen Research & Development, LLCSmall moleculePhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

210 Active assets in the Follicular Lymphoma Grade III (FL III°) cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB

View all 50 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →